{"slug":"tesamorelin-gut","verification":{"valid":true,"entries":2,"head":"c883d0e210003477d52ebf68ba6c21e91966cb4db5fd1488d93e92440503bc0b"},"energy":{"passes":2,"tokens_in":39216,"tokens_out":2746,"tokens_total":41962,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"c883d0e210003477d52ebf68ba6c21e91966cb4db5fd1488d93e92440503bc0b"},"provenance":[{"ts":"2026-06-29T23:20:59.247Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: Tesamorelin for Gut\nSlug: tesamorelin-gut\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"tesamorelin\",\"name\":\"Tesamorelin\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"tesamorelin\",\"name\":\"Tesamorelin\",\"section_title\":\"Why Tesamorelin might help you\",\"layer\":\"GH axis / visceral fat\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, Tesamorelin is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **Tesamorelin** → GH axis / visceral fat\",\"section_headings\":[\"What's breaking down\",\"Why Tesamorelin might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Eac","response":"{\n  \"slug\": \"tesamorelin-gut\",\n  \"title\": \"Tesamorelin and Visceral Abdominal Fat: What Human Trials Show on GH Axis Effects\",\n  \"body\": \"## What's breaking down\\n\\nExcess visceral fat accumulates around abdominal organs, including areas near the gut. This layer sits deep and can press on digestive structures. Growth hormone pulses often decline with age or certain conditions, shifting fat storage toward visceral deposits rather than subcutaneous. If visceral fat builds faster than the body clears it, abdominal girth increases and metabolic stress on nearby tissues rises. Tesamorelin targets the GH axis to address this specific deposition pattern.\\n\\n## Why Tesamorelin might help you\\n\\n1. Tesamorelin acts as a growth hormone-releasing hormone analog. It stimulates the pituitary to release more of your own growth hormone in pulses.\\n2. Higher pulsatile GH increases IGF-1 and shifts fat metabolism away from visceral storage.\\n3. Therefore for you: If visceral fat around abdominal organs forms part of your picture, the compound is discussed because it supports selective reduction in that compartment rather than blanket suppression of appetite or inflammation.\\n4. Reduced visceral fat lowers mechanical pressure on abdominal contents and improves lipid markers in studied populations.\\n5. The effect occurs without major loss of subcutaneous fat or lean mass in the key trials.\\n\\n## How these fit together\\n\\nSingle-compound focus. Tesamorelin maps directly to the GH axis and visceral fat layer. No sibling peptides are in scope, so the discussion stays on this pathway alone.\\n\\n## What the evidence actually shows\\n\\nHuman data come from Phase 3 randomized, double-blind, placebo-controlled trials in HIV patients with excess abdominal fat. Two trials totaling 816 participants showed 15-18% reduction in visceral adipose tissue after 26 weeks at 2 mg daily subcutaneous. Visceral fat dropped while subcutaneous fat stayed stable. Triglycerides fell and body image scores improved","tokens_in":39216,"tokens_out":2746,"cost":0,"prev":"genesis","hash":"fcdc1e467e0f76264798c5742859889167c45a5f6ae8b0f0413b6885be3da66a"},{"ts":"2026-07-17T02:42:23.104Z","model":"owner","action":"voxel_divide","prompt":"","input":"tesamorelin-gut","response":"18 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"fcdc1e467e0f76264798c5742859889167c45a5f6ae8b0f0413b6885be3da66a","hash":"c883d0e210003477d52ebf68ba6c21e91966cb4db5fd1488d93e92440503bc0b"}]}